New hope for rare breast condition: drug targets stubborn inflammation
NCT ID NCT07595900
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether tocilizumab, an anti-inflammatory drug, can help women with a rare breast condition called granulomatous lobular mastitis that hasn't improved with steroids. About 31 women aged 20-50 will receive two doses of the drug intravenously. The main goal is to see if inflammation goes down within 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tocilizumab (a drug that blocks IL-6, a protein involved in inflammation)
- What this could lead to
- If successful, this could provide a new treatment option for people with a rare, painful breast condition that doesn't respond to steroids.
- What could go wrong
- This is a very early, small trial (31 people) with no comparison group, so results may not be conclusive. Tocilizumab also has known risks like serious infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOUS LOBULAR MASTITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.